American Journal of Cardiovascular Drugs

, Volume 8, Issue 1, pp 51–67 | Cite as

Amlodipine/Atorvastatin Fixed-Dose Combination

A Review of its Use in the Prevention of Cardiovascular Disease and in the Treatment of Hypertension and Dyslipidemia
Apis Drug Evaluation



Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase inhibitor atorvastatin. In Europe, the combination is indicated for the prevention of cardiovascular events in hypertensive patients with three concomitant cardiovascular risk factors and, in the US, it is indicated for the management of hypertension and dyslipidemia in patients for whom treatment with both agents is appropriate.

In clinical trials, the fixed-dose combination of amlodipine/atorvastatin effectively managed two important risk factors simultaneously in hypertensive patients at risk of cardiovascular disease or in those with concomitant hypertension and dyslipidemia. The combination is bioequivalent to amlodipine and atorvastatin given alone and does not modify the efficacy of either single agent. Amlodipine/atorvastatin is generally well tolerated, with a tolerability profile consistent with that of each single agent. Compared with the coadministration of each single agent, the convenience of single-pill amlodipine/atorvastatin has the potential to improve patient adherence and the management of cardiovascular risk in selected patients, thereby improving clinical outcomes.

Pharmacologic Properties

Amlodipine is a dihydropyndine calcium channel blocker that inhibits extracellular calcium influx into vascular smooth muscle via blockade of L-type calcium channels causing relaxation of vascular smooth muscle leading to a reduction in BP. Atorvastatin is an HMG-CoA reductase inhibitor that impedes mevalonic acid formation, which subsequently reduces cholesterol formation and increases the rate of low-density lipoprotein-cholesterol (LDL-C) clearance from plasma. The combined administration of amlodipine and atorvastatin may have an additive or potentially synergistic beneficial effect on atherosclerotic plaque formation and some molecular markers of endothelial function.

Administration of the fixed-dose combined amlodipine/atorvastatin tablet does not alter the rate or extent of absorption of either agent. Oral amlodipine peak plasma concentrations (Cmax) are achieved in 6–12 hours. Amlodipine undergoes hepatic metabolism with an elimination half-life (t½β) of ≈30–50 hours. Oral atorvastatin is rapidly absorbed, with Cmax occurring within 1–2 hours. Atorvastatin is metabolized to active ortho- and para-hydroxylated derivatives, which are equipotent to the parent drug in vitro. Active metabolites account for about 70% of the lipid-lowering activity in plasma. Cytochrome P450 (CYP) 3A4 is involved in the metabolism of atorvastatin. The parent drug and its metabolites undergo hepatic metabolism, with t½β values of ≈14 hours and 20–30 hours.

Therapeutic Efficacy

In hypertensive patients with average or below-average LDL-C values in ASCOT-LLA, significantly fewer of those randomized to atorvastatin plus an antihypertensive regimen (either amlodipine or atenolol based) experienced a nonfatal myocardial infarction or fatal coronary heart disease (CHD; primary endpoint) than those randomized to placebo plus an antihypertensive regimen. In a prespecified 2×2 factorial analysis of data from ASCOT-LLA, the risk of nonfatal myocardial infarction and fatal CHD was reduced more in patients receiving atorvastatin plus amlodipine-based treatment than in those receiving atorvastatin plus atenolol-based treatment.

Amlodipine plus atorvastatin once daily demonstrated greater antihypertensive efficacy than atorvastatin alone, and better lipid-lowering efficacy than amlodipine alone, in two randomized, double-blind, placebo-controlled, multicenter studies in patients with hypertension and dyslipidemia. In one study, after 8 weeks of therapy, the percentages of patients who achieved both their BP and LDL-C goals in the groups receiving amlodipine 5 mg plus atorvastatin 10 mg, amlodipine 5 mg plus placebo, atorvastatin 10 mg plus placebo, and placebo plus placebo were 45.5%, 8.3%, 28.6%, and 3.5%, respectively. After a further 12 weeks of nonblind, titration-to-goal treatment with varying dosages of combined therapy, the percentage of patients achieving both goals increased to 67.1%.

In titration-to-goal, noncomparative, prospective, multicenter studies in hypertensive patients with dyslipidemia, the percentage of patients achieving both their BP and LDL-C goals after 14–16 weeks’ treatment with any of 8 fixed-dose combination tablets of amlodipine/atorvastatin once daily ranged from 50.6% to 62.9%. In two prospective subgroup analyses, the proportions of patients with diabetes achieving both goals were 28.6% and 43.6%, and those for patients with metabolic syndrome (as defined by the National Cholesterol Education Program Adult Treatment Panel III) were 45.5% and 55.3%.


The fixed-dose combination of amlodipine/atorvastatin is generally well tolerated in patients with hypertension with or without dyslipidemia, with an overall tolerability profile similar to those of each single agent. In clinical trials, the most common treatment-related adverse events associated with amlodipine and atorvastatin administered as a fixed-dose combination or concomitantly as separate agents were peripheral edema, myalgia, and sinusitis. Most adverse events were mild to moderate in severity.

In a large, double-blind trial, the rate of treatment discontinuation for any reason was 7.7% in the amlodipine 5 mg plus atorvastatin 10 mg group, 7.0% in the amlodipine 5 mg group, 7.5% in the atorvastatin 10 mg group, and 9.6% in the placebo group.


  1. 1.
    World Health Organization Global Report. Preventing chronic disease: a vital investment [online]. Available from URL: disease report [Accessed 2007 Nov 12].Google Scholar
  2. 2.
    Rosamund W, Flegal K, Friday G, et al. Heart disease and stroke statistics: 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(5): e69–171.CrossRefGoogle Scholar
  3. 3.
    Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 2004; 10: 926–32.PubMedGoogle Scholar
  4. 4.
    Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (1 Pt 2): 3S–10S.PubMedCrossRefGoogle Scholar
  5. 5.
    Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. Int J Clin Pract 2005 Jul; 59(7): 839–46.Google Scholar
  6. 6.
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. Circulation 2007; 115: 2761–88.PubMedCrossRefGoogle Scholar
  7. 7.
    Jackson R, Lawes CMM, Bennertt DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005; 365: 434–41.PubMedGoogle Scholar
  8. 8.
    Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591–603.PubMedCrossRefGoogle Scholar
  9. 9.
    The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462–536.PubMedGoogle Scholar
  10. 10.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361(9364): 1149–58.Google Scholar
  11. 11.
    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Heart Protection Study Collaborative Group. MRC/BHF health protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.CrossRefGoogle Scholar
  13. 13.
    Kostis BK. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther 2007; 21: 297–309.PubMedCrossRefGoogle Scholar
  14. 14.
    Battleman DS, Peterson ED. Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among U.S. adults in 2000, utilizing data from the National Health and Nutrition Examination Survey [abstract]. J Manag Care Pharm 2004; 10(2): 186.Google Scholar
  15. 15.
    Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 Suppl.: 2–6.Google Scholar
  17. 17.
    Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333(15): El–6.Google Scholar
  18. 18.
    Chung M, Calcagni A, Glue P, et al. Bioavailability of amlodipine besylate/ atorvastatin calcium combination tablet. J Clin Pharmacol 2006 Sep; 46(9): 1030–7.Google Scholar
  19. 19.
    Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50(3): 560–86.PubMedCrossRefGoogle Scholar
  20. 20.
    Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61(12): 1835–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Kass RS, Arena JP, DiManno D. Block of heart calcium channels by amlodipine: influence of drug charge on blocking activity. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S45–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Murdoch D, Heel RC. Amlodipine: a review of its pharmacological and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991; 41(3): 478–505.PubMedCrossRefGoogle Scholar
  23. 23.
    Pfizer Labs. Caduet (amlodipine besylate/atorvastatin calcium) tablets: description [online]. Available from URL: [Accessed 2007 Sep 18].Google Scholar
  24. 24.
    Burris JF, Allenby KS, Mroczek WJ. The effect of amlodipine on ambulatory blood pressure in hypertensive patients. Am J Cardiol 1994; 73 Suppl.: 39A–43A.PubMedCrossRefGoogle Scholar
  25. 25.
    Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335(15): 1107–14.PubMedCrossRefGoogle Scholar
  26. 26.
    Jukema JW, van der Hoorn JW. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin Pharmacother 2004 Feb; 5(2): 459–68.Google Scholar
  27. 27.
    Delsing DJ, Jukema JW, van de Wiel MA, et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 2003 Jul; 42(1): 63–70.Google Scholar
  28. 28.
    van de Poll SW, Delsing DJ, Wouter Jukema J, et al. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol 2003 Jan; 35(1): 109–18.Google Scholar
  29. 29.
    van de Poll SW, Delsing DJ, Jukema JW, et al. Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002 Sep; 164(1): 65–71.Google Scholar
  30. 30.
    Martin-Ventura JL, Tunon J, Duran MC, et al. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients. J Am Soc Nephrol 2006 Dec; 17 (12 Suppl. 3): S189–93.Google Scholar
  31. 31.
    Mason RP. A rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5(6): 489–501.PubMedCrossRefGoogle Scholar
  32. 32.
    Mason RP, Kubant R, Malinski C, et al. Combination of amlodipine and atorvastatin reverses age-dependent endothelial dysfunction in rat aorta [abstract no. 1002–7]. JACC 2007 Mar 6; 49(9 Suppl. A): 316.Google Scholar
  33. 33.
    Cohn JN, Neutel J, Houston M, et al. Early improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia: the AVALON arterial wall compliance (AWC) trial [abstract no. LB-3]. 20th Annual Scientific Meeting of the American Society of Hypertension; 2005 May 14–18; San Francisco (CA).Google Scholar
  34. 34.
    Leibovitz E, Beniashvili M, Zimlichman R, et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 2003 Sep; 16 (9 Pt 1): 715–8.Google Scholar
  35. 35.
    Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 2006 Oct; 62: 817–22.Google Scholar
  36. 36.
    Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004 Sep; 17(9): 823–7.Google Scholar
  37. 37.
    Charbonneau F, Anderson TJ, Title L, et al. Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MAR-GAUX). Atherosclerosis Epub 2007 Jun.Google Scholar
  38. 38.
    Chung M, Calcagni A, Glue P, et al. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 2006 Oct; 46(10): 1212–6.Google Scholar
  39. 39.
    Whitfield LR, Stern RH, Sedman AJ, et al. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet 2000; 25(2): 97–101.PubMedCrossRefGoogle Scholar
  40. 40.
    Siedlik PH, Olson SC, Yang B-B, et al. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999; 39: 501–4.PubMedGoogle Scholar
  41. 41.
    Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91–8.PubMedCrossRefGoogle Scholar
  42. 42.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288(23): 2981–97.CrossRefGoogle Scholar
  43. 43.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004; 292(18): 2217–26.PubMedCrossRefGoogle Scholar
  45. 45.
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.PubMedCrossRefGoogle Scholar
  46. 46.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–504.PubMedCrossRefGoogle Scholar
  47. 47.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291(9): 1071–80.PubMedCrossRefGoogle Scholar
  48. 48.
    Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens 2006 Aug; 8(8): 571–81.Google Scholar
  49. 49.
    Blank R, Lasalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens 2005 May; 7(5) 264–73.Google Scholar
  50. 50.
    Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J Clin Pharmacol 2007; 47: 1555–69.PubMedCrossRefGoogle Scholar
  52. 52.
    Hobbs FDR, Gensini G, Mancini GBJ, et al. Utility of amlodipine/atorvastatin single-pill therapy in patients with diabetes mellitus or metabolic syndrome: Results from the JEWEL programme [abstract no. 1029]. Diabetologia 2006 Sep; 49 Suppl. 1: 629. Plus poster presented at the 42nd Annual Meeting of the European Association for the Study of Diabetes; 2006 Sep 14–17; Copenhagen.Google Scholar
  53. 53.
    Flack JM, Victor R, Watson K, et al. Amlodipine/atorvastatin single pill improves goal attainment in the treatment of hypertension and dyslipidemia in African Americans: the CAPABLE trial [abstract]. J Clin Hypertens 2006; 8(6): 456.Google Scholar
  54. 54.
    Aguilar-Salinas CA, Ro Y, Tse HF, et al. Clinical utility of single-pill amlodipine besylate/atorvastatin calcium for the attainment of blood pressure and lipid goals in patients of diverse ethnicity with diabetes: results from the GEMINI-AALA Study [abstract no. 1163]. Diabetologia 2007; 50 Suppl. 1: 478. Plus poster presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes; 2007 Sep 17–21; Amsterdam.Google Scholar
  55. 55.
    Ro Y-M, Tse HF, Howes L, et al. Clinical utility of single-pill amlodipine/ atorvastatin therapy in Asian patients with hypertension and dyslipidemia [abstract no. PO3-80]. J Hypertens 2006 Dec; 24 Suppl. 6: 329.Google Scholar
  56. 56.
    Tse HF, Ro YM, Howes L, et al. Multiple-risk intervention with single-pill amlodipine/atorvastatin therapy helps patients with diverse ethnicity attain recommended therapeutic goals for blood pressure and lipids (the GEMINI-AALA study) [abstract no. PO3-79]. J Hypertens 2006; 24 Suppl. 6: 329.Google Scholar
  57. 57.
    Erdine S, Ro Y, Tse H, et al. Multiple-risk intervention with single-pill amlodipine besylate/atorvastatin calcium therapy helps patients with diverse ethnicity attain recommended therapeutic goals for blood pressure and lipids (The GEMINI-AALA study) [abstract no. 7C.6]. J Hypertens 2007; 25 Suppl. 2: 277.Google Scholar
  58. 58.
    Neutel J, La Salle J, Berman L, et al. Dual goal attainment with amlodipine/ atorvastatin single pill in a broad range of patients: results from the Gemini study [abstract no. P410]. Am J Hypertens 2004; 17 (5 Pt 2): 184.CrossRefGoogle Scholar
  59. 59.
    Feldman R. Multiple risk intervention with a single-pill combination (amlodipine/ atorvastatin) helps patients to attain recommended target levels for blood pressure and lipids (The JEWEL Program) [abstract no. P-129B]. J Clin Hypertens 2006 Jun; 8(6): 457.Google Scholar
  60. 60.
    Hobbs FD, Gensini G, Mancini GB, et al. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol 2006; 110: 242–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–46.CrossRefGoogle Scholar
  62. 62.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72.Google Scholar
  63. 63.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 May 16; 285(19): 2486–97.Google Scholar
  64. 64.
    Merikle EP, Marcucci G, Evans C. Satisfaction with a single pill treatment of hypertension and dyslipidemia [abstract no. 1780]. 13th Annual Conference of the International Society for Quality of Life Research; 2006 Oct 10–14; Lisbon, 44–45.Google Scholar
  65. 65.
    Smith TW, Cherry SB, Tang SSK, et al. Clinical and economic consequences of a single-pill combination of amlodipine/atorvastatin compared with a two-pill regimen in hypertensive patients with additional cardiovascular risk factors [abstract no. P4800]. Eur Heart J 2007; 28(Abstr Suppl.): 857.Google Scholar
  66. 66.
    Lindgren P, Buxton M, Kahan T, et al. Amlodipine + atorvastatin is cost-effective compared to atenolol + atorvastatin, amlodipine or atenolol alone: the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) [abstract no. P4801]. Eur Heart J 2007; 28(Abstr Suppl.): 857.Google Scholar
  67. 67.
    Jönsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5–10.PubMedCrossRefGoogle Scholar
  68. 68.
    Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 158: 577–83.PubMedCrossRefGoogle Scholar
  69. 69.
    Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006; 97: 61–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Leeper NJ, Ardehali R, deGoma EM, et al. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation 2007; 116: 613–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Williams B, Lacy PS, Thom SM. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006; 113: 1213–25.PubMedCrossRefGoogle Scholar
  72. 72.
    Jukema JW, Zwinderman AH, van Boven AJ, et al. Evidence for the synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Atheroscler Thromb Vase Biol 1996; 16: 425–30.CrossRefGoogle Scholar
  73. 73.
    Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147–52.PubMedCrossRefGoogle Scholar
  74. 74.
    Patel BV, Tang SS, Thiebaud P, et al. A single pill combining antihypertensive and statin therapies improves patient adherence compared with multi-drug combinations in managing multiple cardiovascular risk [abstract no. OS20-6]. J Hypertens 2006; 24 Suppl. 6: 65.Google Scholar
  75. 75.
    Benner JS, Smith TW, Petrilla AA, et al. Coronary heart disease events and associated costs in US adults with uncontrolled hypertension and multiple cardiovascular risk factors [abstract no. P-595]. Am J Hypertens 2005; 18 (5 Pt 2): 224A. Plus poster presented at the American Society of Hypertension 20th Annual Scientific Meeting and Exposition; 2005 May 14–18; San Francisco.Google Scholar
  76. 76.
    Reddy KS. The preventative polypill — much promise, insufficient evidence. N Engl J Med 2007; 356(3): 212.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Wolters Kluwer Health /AdisNew Zealand
  2. 2.Editorial office of Wolters Kluwer HealthConshohockenUSA

Personalised recommendations